Risks and Mitigation Strategies for the Storage and Transportation of Finished Drug Products
The USP general chapter on good storage and distribution practice for finished drug products, official 1 February 2021 in its risk-based form. <1079> frames storage and transportation as a risk-management exercise — identify the hazards a product faces between manufacturer and patient, then mitigate with qualified storage, transport controls, and monitoring. It anchors a family of sub-chapters: <1079.1> investigational products, <1079.2> mean kinetic temperature, <1079.3> monitoring devices, and <1079.4> temperature mapping.
What this does not cover
stated in the document's own scope- Covers finished drug products in storage and transportation; active-substance distribution is addressed by GDP frameworks such as the EU 2015 API guidelines, not this chapter.
- An informational chapter above <1000>: it is not mandatory compendial text unless a regulator, contract, or licensing framework invokes it.
- Provides risk and mitigation guidance; the stability data defining a product's tolerance to excursions come from the manufacturer's ICH-based stability programme.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
USP General Chapter <1079>, Risks and Mitigation Strategies for the Storage and Transportation of Finished Drug Products, is the United States Pharmacopeia's good storage and distribution practice chapter, official in its risk-based form since 1 February 2021. It frames the journey from manufacturer to patient as a risk-management exercise: identify the hazards a finished drug product faces at each storage and transportation step, evaluate them against the product's labelled conditions and stability data, and mitigate with qualified storage, appropriate packaging and transport controls, and monitoring. The chapter anchors a family of sub-chapters — <1079.1> on investigational drug products, <1079.2> on mean kinetic temperature in evaluating excursions, <1079.3> on time, temperature, and humidity monitoring devices, and <1079.4> on temperature mapping of storage areas.
Scope & applicability
Storage and transportation of finished drug products across the US supply chain — manufacturers, distributors, and dispensers. As an above-<1000> informational chapter it is not mandatory compendial text, but it is the reference US practice standard for good storage and distribution.
Legal basis & how it acquires force
A USP-NF general chapter numbered above <1000>, which makes it informational: it is not made mandatory by reference from General Notices or a monograph, and USP itself enforces nothing. It acquires practical force as the recognised US practice standard for storage and distribution — referenced in quality agreements, state licensing frameworks, and accreditation schemes — and through the general expectation that drug products be held under labelled conditions, which the CGMP holding requirements impose.
Document structure
| Part | Covers |
|---|---|
| Scope and risk framework | The supply-chain steps covered and the risk-based approach to storage and transportation hazards |
| Storage | Maintaining labelled storage conditions, qualified storage areas, and evaluation of excursions against stability data |
| Transportation | Transport hazards, packaging and lane considerations, and controls preserving product quality in transit |
| Roles across the supply chain | Responsibilities of manufacturers, distributors, and dispensers for maintaining product quality |
| The <1079.x> sub-chapter family | Investigational products (<1079.1>), mean kinetic temperature (<1079.2>), monitoring devices (<1079.3>), and temperature mapping (<1079.4>) |
Key requirements
- Assess the risks to product quality across each storage and transportation step
- Store and transport products within labelled conditions, with excursions evaluated against stability data
- Use mean kinetic temperature appropriately in evaluating temperature excursions (per <1079.2>)
- Select and use time, temperature, and humidity monitoring devices suited to the risk (per <1079.3>)
- Qualify storage areas through temperature mapping (per <1079.4>)
Implementation tips
- MKT is an evaluation tool for short-term excursions, not a device for averaging away sustained storage problems — <1079.2> is explicit about that boundary
Revision notes
The risk-based revision of <1079> became official 1 February 2021, replacing the earlier good-storage-and-shipping-practices chapter and spawning the <1079.1>–<1079.4> sub-chapter family.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
Chapter <1079> is the US counterpart of the EU GDP guidelines' temperature-management provisions and the WHO storage-and-transport guidance in TRS 961 Annex 9, and it is complemented by the engineering methodology of PDA Technical Report No. 39. Its mean-kinetic-temperature sub-chapter <1079.2> supplies the calculation the EU and WHO texts assume when excursions are evaluated against MKT.
USP <1079>: frequently asked questions
Quick answers to common questions about USP <1079>.
Is USP <1079> mandatory?
No. General chapters numbered above <1000> are informational, and USP enforces nothing itself. <1079> functions as the recognised US practice standard for good storage and distribution, and it becomes contractually or legally relevant where quality agreements, state licensing rules, or regulators reference it.
What is mean kinetic temperature and how may it be used?
Mean kinetic temperature is a single calculated temperature that weights higher temperatures more heavily, reflecting their greater effect on degradation. Under <1079.2> it is a tool for evaluating short-term temperature excursions against a product's storage claim — not a device for averaging away sustained storage outside labelled conditions.
What are the <1079> sub-chapters?
<1079.1> covers storage and transportation of investigational drug products; <1079.2> covers mean kinetic temperature in evaluating excursions; <1079.3> covers time, temperature, and humidity monitoring devices; and <1079.4> covers temperature mapping for the qualification of storage areas.
When did the current <1079> become official?
The risk-based revision became official on 1 February 2021, replacing the earlier good-storage-and-shipping-practices text and establishing the current chapter family.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.